Fziomed, Inc. Showcases Game-Changing Adhesion Barrier Gel at 2025 Global Hand Congress

Fziomed, Inc., a leading name in postsurgical adhesion prevention, is set to attend the 2025 IFSSH and IFSHT Triennial Global Hand Congress from March 24-28 in Washington, D.C. The event is jointly hosted by prominent organizations such as the American Society for Surgery of the Hand, the American Society of Hand Therapists, and the American Association for Hand Surgery. Fziomed will proudly highlight its flagship product, the Dynavisc® Adhesion Barrier Gel, which recognizes the need for effective solutions in postoperative recovery, particularly for tendon and peripheral nerve surgeries.

A Revolutionary Approach to Prevention

Dynavisc® stands out in the market as the only synthetic dual-polymer technology available, specifically engineered to minimize adhesion formation after crucial surgical procedures. Since its inception, Fziomed has cultivated a reputation for innovation and efficacy in the realm of surgical materials, boasting over 20 years of clinical use. The product's design allows for a temporary physical barrier between tissues, which is pivotal in mitigating postoperative complications such as pain and limited range of motion.

Dr. Gere diZerega, Fziomed's Medical Director, emphasizes the importance of employing such technology, stating, "Even with the best surgical technique, postoperative adhesions can form following tendon and peripheral nerve procedures." His insights underline the necessity for surgeons to utilize effective barrier methods to maximize patients' surgical outcomes.

Seamless Application and Proven Safety

What sets Dynavisc apart is its user-friendly application that complements a surgeon's workflow. The gel comes with a specialized applicator that simplifies its use while ensuring excellent visibility during the procedure. Unlike other products, Dynavisc requires no refrigeration or complicated handling processes, making it an accessible option for healthcare professionals seeking reliable solutions for adhesion prevention.

Paul Mraz, CEO of Fziomed, remarked on the significance of their adhesion barriers, saying, "We are excited to offer surgeons an easy-to-use and time-tested technology designed to preserve their surgical excellence and provide better outcomes for patients." The commitment to creating an intuitive, effective product reflects Fziomed's dedication to improving surgical practices and enhancing recovery experiences for patients worldwide.

A Testament to Performance

The dual-polymer technology that underpins Fziomed's products has been rigorously tested and has garnered approval in over 70 countries. It has been involved in nearly 1 million surgical procedures globally since 2002, affirming its reliability and effectiveness in real-world applications. The Dynavisc Adhesion Barrier Gel exemplifies Fziomed's relentless pursuit of excellence in the field of surgical biomaterials.

Fziomed invites attendees of the Global Hand Congress to visit Booth #809, where they can gain deeper insights into Dynavisc and its clinical applications. This congress serves not just as a platform for Fziomed to display its innovations but as an opportunity to engage with healthcare professionals who share a commitment to advancing surgical care.

In summary, Fziomed’s dedication to innovation in adhesion prevention technology underscores its role as a leader in the medical device industry, particularly in enhancing surgical outcomes. With the introduction of Dynavisc, healthcare providers are better equipped to combat the complexities associated with postoperative recovery, promising a brighter future for patients undergoing tendon and nerve surgeries.

For more information about Fziomed and its pioneering products, please visit fziomed.com. However, it's important to note that Dynavisc is not yet FDA cleared for use in the United States, and further regulatory approvals are pending.